These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 32897759

  • 1. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
    Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ.
    Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008123. PubMed ID: 32897759
    [Abstract] [Full Text] [Related]

  • 2. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC, Tomson TT, Knight BP, Bonow RO, Choudhury L.
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [Abstract] [Full Text] [Related]

  • 3. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [Abstract] [Full Text] [Related]

  • 4. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K, Suzuki A, Shiga T, Minami Y, Arai K, Ashihara K, Shoda M, Hagiwara N.
    BMC Cardiovasc Disord; 2021 Feb 19; 21(1):106. PubMed ID: 33607967
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA.
    Europace; 2013 Mar 19; 15(3):347-54. PubMed ID: 23002195
    [Abstract] [Full Text] [Related]

  • 6. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 7. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.
    JAMA; 2007 Jul 25; 298(4):405-12. PubMed ID: 17652294
    [Abstract] [Full Text] [Related]

  • 8. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D.
    Heart Rhythm; 2021 Jan 25; 18(1):63-70. PubMed ID: 32800967
    [Abstract] [Full Text] [Related]

  • 9. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.
    Heart Rhythm; 2013 Feb 25; 10(2):214-8. PubMed ID: 23041573
    [Abstract] [Full Text] [Related]

  • 10. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.
    Circ Arrhythm Electrophysiol; 2016 Mar 25; 9(3):. PubMed ID: 26966288
    [Abstract] [Full Text] [Related]

  • 11. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS.
    J Am Heart Assoc; 2016 Feb 12; 5(2):. PubMed ID: 26873684
    [Abstract] [Full Text] [Related]

  • 12. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P, Adduci C, Palano F, Semprini L, Serdoz A, Montesanti D, Santini D, Musumeci B, Salvati A, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2015 Aug 12; 26(8):893-899. PubMed ID: 25996259
    [Abstract] [Full Text] [Related]

  • 13. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P, Katsanos S, Joyce E, VAN DEN Brink OV, Atsma DE, Schalij MJ, Bax JJ, Delgado V, Marsan NA.
    J Cardiovasc Electrophysiol; 2015 May 12; 26(5):547-55. PubMed ID: 25648421
    [Abstract] [Full Text] [Related]

  • 14. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B, Dale Z, Carrassa G, Reza N, Ustunkaya T, Papoutsidakis N, Gray A, Howell SJ, Elman MR, Pieragnoli P, Ricciardi G, Jacoby D, Frankel DS, Owens A, Olivotto I, Heitner SB.
    Heart Rhythm; 2020 Jul 12; 17(7):1107-1114. PubMed ID: 32084597
    [Abstract] [Full Text] [Related]

  • 15. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
    Rigopoulos AG, Daci S, Pfeiffer B, Papadopoulou K, Neugebauer A, Seggewiss H.
    Clin Res Cardiol; 2016 Nov 12; 105(11):953-961. PubMed ID: 27270758
    [Abstract] [Full Text] [Related]

  • 16. Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy.
    Francia P, Adduci C, Semprini L, Palano F, Santini D, Musumeci B, Santolamazza C, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2017 Jan 12; 28(1):103-108. PubMed ID: 27862589
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA, Spirito P.
    N Engl J Med; 2000 Feb 10; 342(6):365-73. PubMed ID: 10666426
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH, Lin YJ, Huang JL, Wu TJ, Cheng CC, Lin WS, Tuan TC, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Tsai CF, Tsao HM, Chen SA.
    J Cardiovasc Electrophysiol; 2012 Jul 10; 23(7):750-6. PubMed ID: 22353378
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Glikson M.
    Europace; 2014 Feb 10; 16(2):227-34. PubMed ID: 24108231
    [Abstract] [Full Text] [Related]

  • 20. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.
    Wu KC, Gerstenblith G, Guallar E, Marine JE, Dalal D, Cheng A, Marbán E, Lima JA, Tomaselli GF, Weiss RG.
    Circ Cardiovasc Imaging; 2012 Mar 10; 5(2):178-86. PubMed ID: 22267750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.